Avastin sBLA Clears Advisory Committee, Faces Quality of Life Hurdle
This article was originally published in The Pink Sheet Daily
Accelerated approval for glioblastoma multiforme can be based on objective response rate, panel tells FDA.
You may also be interested in...
FDA questions whether imaging improvements in patients with glioblastoma metaforme are sufficient to denote clinical change.
Approval of temozolomide was based on a Phase III trial that demonstrated a statistically significant survival benefit in combination with radiotherapy versus radiotherapy alone. Temodar also received full approval for its original indication of anaplastic astrocytoma.
Guilford's marketing of Gliadel for use in patients undergoing surgery for newly-diagnosed malignant glioma will highlight the survival benefit, the company said after receiving the supplemental indication